Literature DB >> 21062406

Comparison between L-CHOP and an L-CHOP protocol with interposed treatments of CCNU and MOPP (L-CHOP-CCNU-MOPP) for lymphoma in dogs.

K M Rassnick1, D B Bailey, E K Malone, J L Intile, M A Kiselow, A B Flory, L L Barlow, C E Balkman, S M Barnard, A H Waite.   

Abstract

An L-CHOP protocol with interposed treatments of CCNU and MOPP (L-CHOP-CCNU-MOPP) was evaluated in 66 dogs with stages III-V lymphoma. Results were compared with a historical group of 71 dogs treated with an L-CHOP protocol. Complete remission (CR) rates (85 and 80%, respectively) did not differ significantly between protocols (P = 0.48). First CR duration for dogs treated with L-CHOP-CCNU-MOPP was significantly longer: median, 317 days; 2-year CR rate, 35% versus median, 298 days; 2-year CR rate, 13%, P = 0.05). For the L-CHOP-CCNU-MOPP protocol, dogs in substage-b had a 4.3 times greater hazard of having a relapse than dogs in substage-a (P = 0.002). Frequency of adverse chemotherapy-associated gastrointestinal effects did not differ between protocols (P = 0.77). Neutropenia (primarily after CCNU) occurred more frequently in dogs treated with L-CHOP-CCNU-MOPP (P < 0.001). In summary, the L-CHOP-CCNU-MOPP protocol showed an improved duration of first CR as compared with an L-CHOP protocol, but the relevance of this finding might be subject to clinical judgement.
© 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21062406     DOI: 10.1111/j.1476-5829.2010.00224.x

Source DB:  PubMed          Journal:  Vet Comp Oncol        ISSN: 1476-5810            Impact factor:   2.613


  8 in total

1.  Hypersensitivity reactions associated with L-asparaginase administration in 142 dogs and 68 cats with lymphoid malignancies: 2007-2012.

Authors:  Mary Kay Blake; Brittany J Carr; Glenna E Mauldin
Journal:  Can Vet J       Date:  2016-02       Impact factor: 1.008

2.  Impact of Pretreatment Neutrophil Count on Chemotherapy Administration and Toxicity in Dogs with Lymphoma Treated with CHOP Chemotherapy.

Authors:  Q Fournier; J-C Serra; I Handel; J Lawrence
Journal:  J Vet Intern Med       Date:  2017-12-04       Impact factor: 3.333

3.  Metabolic Abnormalities Detected in Phase II Evaluation of Doxycycline in Dogs with Multicentric B-Cell Lymphoma.

Authors:  Kelly R Hume; Skylar R Sylvester; Lucia Borlle; Cheryl E Balkman; Angela L McCleary-Wheeler; Mary Pulvino; Carla Casulo; Jiyong Zhao
Journal:  Front Vet Sci       Date:  2018-02-26

4.  Evaluation of serum thymidine kinase 1 activity as a biomarker for treatment effectiveness and prediction of relapse in dogs with non-Hodgkin lymphoma.

Authors:  Pierre Boyé; Franck Floch; François Serres; Kévyn Geeraert; Pierre Clerson; Xavier Siomboing; Mattias Bergqvist; Gabriel Sack; Dominique Tierny
Journal:  J Vet Intern Med       Date:  2019-05-25       Impact factor: 3.333

5.  RNA disruption indicates CHOP therapy efficacy in canine lymphoma.

Authors:  Amadeo M Parissenti; Laura B Pritzker; Baoqing Guo; Rashmi Narendrula; Shirly Xiaohui Wang; Lin Laura Lin; Jingchun Pei; Karolina Skowronski; Dorothee Bienzle; J Paul Woods; Kenneth P H Pritzker; Brenda L Coomber
Journal:  BMC Vet Res       Date:  2019-12-16       Impact factor: 2.741

6.  Liquid biopsy based on small extracellular vesicles predicts chemotherapy response of canine multicentric lymphomas.

Authors:  Taismara K Garnica; Jéssika C C Lesbon; Ana C F C M Ávila; Arina L Rochetti; Oscar R S Matiz; Roana C S Ribeiro; Aline Zoppa; Adriana T Nishiya; Mirela T Costa; Andrigo B de Nardi; David J Argyle; Ricardo F Strefezzi; Juliano C Silveira; Heidge Fukumasu
Journal:  Sci Rep       Date:  2020-11-23       Impact factor: 4.379

7.  Evaluation of the Proliferative Activity of Diffuse Large B-Cell Lymphoma (DLBCL) in Dogs with Respect to Patient Eligibility for Anthracycline-Based Chemotherapy.

Authors:  Paweł Klimiuk; Wojciech Łopuszyński; Kamila Bulak; Adam Brzana
Journal:  Animals (Basel)       Date:  2021-04-20       Impact factor: 2.752

8.  Concurrent use of rabacfosadine and L-asparaginase for relapsed or refractory multicentric lymphoma in dogs.

Authors:  Jacob R Cawley; Zachary M Wright; Karri Meleo; Gerald S Post; Craig A Clifford; Kathryn R Vickery; David M Vail; Philip J Bergman; Douglas H Thamm
Journal:  J Vet Intern Med       Date:  2020-02-16       Impact factor: 3.333

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.